Achieve goes up in smoke
Achieve Life Sciences gets a reality check despite largely positive smoking cessation data.
Cymabay can’t buck the Nash disappointment trend
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
ADA 2019 – a good start for Beta Bionics
The iLet system showed decent blood sugar control in its first trial, but the highly automated system is far from proven.
Vertex’s second transformation: Duchenne time
The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.
Rewalk Robotics suits up
Europe and the US approvals of the ReStore device have arrived within a week; now the company must deliver commercially.
VTV’s diabetes reinvention gains some ground
After crashing on a late-stage Alzheimer’s failure last year VTV Therapeutics has taken a small step forward in type 1 diabetes.
Positive data Kalm Cara investors
Cara Therapeutics’ stock shot up 18% today on data derisking two key projects.
Biomarin suffers minimal bleeding on valrox readout
Three-year data from Biomarin’s haemophilia A gene therapy fail to quash concerns about durability, but the company insists that the results are good enough to file on.
Zolgensma heads up spate of US approvals
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.